Neurobiology of Aging
Volume 29, Issue 5 , Pages 676-692 , May 2008

Hippocampal hypometabolism predicts cognitive decline from normal aging

  • Lisa Mosconi

      Affiliations

    • New York University School of Medicine, New York, NY 10016, USA
    • ,
  • Susan De Santi

      Affiliations

    • New York University School of Medicine, New York, NY 10016, USA
    • ,
  • Juan Li

      Affiliations

    • New York University School of Medicine, New York, NY 10016, USA
    • ,
  • Wai Hon Tsui

      Affiliations

    • New York University School of Medicine, New York, NY 10016, USA
    • Nathan Kline Institute, Orangeburg, NY 10962, USA
    • ,
  • Yi Li

      Affiliations

    • New York University School of Medicine, New York, NY 10016, USA
    • ,
  • Madhu Boppana

      Affiliations

    • New York University School of Medicine, New York, NY 10016, USA
    • ,
  • Eugene Laska

      Affiliations

    • Nathan Kline Institute, Orangeburg, NY 10962, USA
    • ,
  • Henry Rusinek

      Affiliations

    • New York University School of Medicine, New York, NY 10016, USA
    • ,
  • Mony J. de Leon

      Affiliations

    • New York University School of Medicine, New York, NY 10016, USA
    • Nathan Kline Institute, Orangeburg, NY 10962, USA
    • Corresponding Author InformationCorresponding author at: Center for Brain Health, MHL 400, New York University School of Medicine, 560 First Avenue, New York, NY 10016, USA. Tel.: +1 212 263 5805; fax: +1 212 263 3270.

Received 20 April 2006 ,Revised 4 December 2006 ,Accepted 5 December 2006.

References 

  1. Albin RL, Minoshima S, DAmato CJ, Frey KA, Kuhl DE, Sima AAF. Fluoro-deoxyglucose positron emission tomography in diffuse lewy body disease. Neurology. 1996;47:462–466
  2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition), 4th ed., American Psychiatric Association, Washington, D.C., 1994.
  3. Anchisi D, Borroni B, Franceschi M, Kerrouche N, Kalbe E, Beuthien-Beumann B, et al. Heterogeneity of brain glucose metaboism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch. Neurol. 2005;62:1728–1733
  4. Ball MJ, Hachinski V, Fox A, Kirshen AJ, Fisman M, Blume W, et al. A new definition of Alzheimer's disease: a hippocampal dementia. Lancet. 1985;1:14–16
  5. Berent S, Giordani B, Foster N, Minoshima S, Lajiness-O’Neill R, Koeppe R, et al. Neuropsychological function and cerebral glucose utilization in isolated memory impairment and Alzheimer's disease. J. Psychiat. Res. 1999;33:7–16
  6. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239–259
  7. Chetelat G, Desgranges B, De La Sayette V, Viader F, Eustache F, Baron JC. Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer's disease?. Neurology. 2003;60:1374–1377
  8. de Leon MJ, Convit A, Wolf OT, Tarshish CY, De Santi S, Rusinek H, et al. Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-d-glucose/positron-emission tomography (FDG/PET). Proc. Natl. Acad. Sci. U.S.A. 2001;98:10966–10971
  9. De Santi S, de Leon MJ, Rusinek H, Convit A, Tarshish CY, Boppana M, et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol. Aging. 2001;22:529–539
  10. De Santi S, Li J, Reisberg B, Notkin-Schwab R, Rogers K, Williams S, et al. How good are single amnestic and multiple domains for characterizing MCI patients at risk for AD?. Alzh. Dementia. 2005;1:S81
  11. den Heijer T, Geerlings MI, Hoebeek FE, Hofman A, Koudstaal PJ, Breteler M. Use of hippocampal and amygdalar volumes on magnetic resonance imaging to predict dementia in cognitively intact elderly people. Arch. Gen. Psychiat. 2006;63:57–62
  12. Diggle PJ, Heagerty P, Liang K-Y, Zeger SC. Analysis of Longitudinal Data. New York: Oxford University Press; 2002;
  13. Drzezga A, Grimmer T, Riemenschneider M, Lautenschlager N, Siebner H, Alexopoulus P, et al. Prediction of individual outcome in MCI by means of genetic assessment and 18F-FDG PET. J. Nucl. Med. 2005;46:1625–1632
  14. Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur. J. Nucl. Med. 2003;30:1104–1113
  15. Folstein M. The mini-mental state examination. In:  Crook T,  Ferris SH,  Bartus R editor. Assessment in Geriatric Psychopharmacology. New Canaan: Mark Powley Associates; 1983;p. 47–51
  16. Fox NC, Crum WR, Scahill RI, Stevens JM, Janssen JC, Rossor MN. Imaging of onset and progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance images. Lancet. 2001;358:201–205
  17. Fox NC, Warrington EK, Rossor MN. Serial magnetic resonance imaging of cerebral atrophy in preclinical Alzheimer's disease. Lancet. 1999;353:2125
  18. Frank RA, Galasko D, Hampel H, Hardy J, de Leon MJ, Mehta PD, et al. Biological markers for therapeutic trials in Alzheimer's disease: proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol. Aging. 2003;24:521–536
  19. Friston KJ, Holmes AP, Worsley KJ, Poline J-P, Frith CD, Frackowiak RSJ. Statistical parametric maps in functional imaging: a general linear approach. Hum. Brain Mapping. 1995;2:189–210
  20. Friston KJ, Stephan KE, Lund TE, Morcom A, Kiebel SJ. Mixed-effects and fMRI studies. Neuroimage. 2004;24:244–252
  21. Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, et al. Mild cognitive impairment. Lancet. 2006;367:1262–1270
  22. Geerlings MI, Jonker C, Bouter LM, Ader HJ, Schmand B. Association between memory complaints and incident Alzheimer's disease in elderly people with normal baseline cognition. Am. J. Psychiat. 1999;156:531–537
  23. Hachinski VC, Lassen NA, Marshall J. Multi-infarct dementia, a cause of mental deterioration in the elderly. Lancet. 1974;2:207–210
  24. Haxby JV, Grady CL, Koss E, Horwitz B, Heston L, Schapiro M, et al. Longitudinal study of cerebral metabolic asymmetries and associated neuropsychological patterns in early dementia of the Alzheimer type. Arch. Neurol. 1990;47:753–760
  25. Hosmer DW, Lemeshow S. In:  Hosmer DW,  Lemeshow S editor. Parametric Regression Models. New York, NY: Wiley; 1999;p. 289–299
  26. Ibanez V, Pietrini P, Alexander GE, Furey ML, Teichberg D, Rajapakse JC, et al. Regional gluose metabolic abnormalities are not the result of atrophy in Alzheimer's disease. Neurology. 1999;50:1585–1593
  27. Jack CR, Shiung MM, Gunter JL, O’Brien PC, Weigand SD, Knopman DS, et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology. 2004;62:591–600
  28. Jonker C, Geerlings MI, Schmand B. Are memory complaints predictive for dementia? A review of clinical and population-based studies. Int. J. Geriatr. Psych. 2000;15:983–991
  29. Klunk WE, Engler H, Nordberg A, Yanming W, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 2004;55:306–319
  30. Maldjian JA, Laurienti PJ, Kraft RA, Burdette JH. An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. Neuroimage. 2003;19:1233–1239
  31. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health & Human Services Task Force on Alzheimer's disease. Neurology. 1984;34:939–944
  32. Meltzer CC, Leal JP, Mayberg HS, Wagner HN, Frost JJ. Correction of PET data for partial volume effects in human cerebral cortex by MR imaging. J. Comp. Assist. Tomogr. 1990;14:561–570
  33. Mesulam MM. Neuroplasticity failure in Alzheimer's disease: bridging the gap between plaques and tangles. Neuron. 1999;24:521–529
  34. Minoshima S, Frey KA, Foster NL, Kuhl DE. Preserved pontine glucose metabolism in Alzheimer's Disease: a reference region for functional brain image (PET) analysis. J. Comp. Assist. Tomogr. 1995;19:541–547
  35. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann. Neurol. 1997;42:85–94
  36. Morrison JH, Hof PR. Life and death of neurons in the aging brain. Science. 1997;278:412–419
  37. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. Eur. J. Nucl. Med. 2005;32:486–510
  38. Mosconi L, De Santi S, Li Y, Li J, Zhan J, Tsui WH, et al. Visual rating of medial temporal lobe metabolism in mild cognitive impairment and Alzheimer's disease using FDG-PET. Eur. J. Nucl. Med. 2006;33:210–221
  39. Mosconi L, Perani D, Sorbi S, Herholz K, Nacmias B, Holthoff V, et al. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology. 2004;63:2332–2340
  40. Mosconi L, Tsui WH, De Santi S, Rusinek H, Li J, Convit A, et al. Reduced hippocampal metabolism in mild cognitive impairment and Alzheimer's disease: automated FDG-PET Image Analysis. Neurology. 2005;64:1860–1867
  41. Nestor PJ, Fryer TD, Smielewski P, Hodges JR. Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment. Ann. Neurol. 2003;54:343–351
  42. Nestor PJ, Scheltens P, Hodges JR. Advances in the early detection of Alzheimer's disease. Nat. Med. 2004;10:S34–S41
  43. Nicoll JAR, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-[beta] peptide: a case report. Nat. Med. 2003;9:448–452
  44. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 1999;56:303–308
  45. Purser JL, Fillenbaum GG, Wallace RB. Memory complaint is not necessary for diagnosis of mild cognitive impairment and does not predict 10-year trajectories of functional disability, word recall, or short portable mental status questionnaire limitations. J. Am. Geriatr. Soc. 2006;54:335–338
  46. Reed BR, Jagust WJ, Seab JP, Ober BA. Memory and regional cerebral blood flow in mildly symptomatic Alzheimer's disease. Neurology. 1989;39:1537–1539
  47. Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc. Natl. Acad. Sci. U.S.A. 2004;101:284–289
  48. Reisberg B, Ferris SH, de Leon MJ, Crook T. The global deterioration scale for assessment of primary degenerative dementia. Am. J. Psychiat. 1982;139:1136–1139
  49. Reivich M, Alavi A, Wolf A, Fowler J, Russell J, Arnett C, et al. Glucose metabolic rate kinetic model parameter determination in humans: The lumped constants and rate constants for [18F]fluorodeoxyglucose and [11C]deoxyglucose. J. Cereb. Blood Flow Metab. 1985;5:179–192
  50. Rusinek H, Chandra R. Accuracy of tissue volume determination from MRI: a phantom study. Invest Radiol. 1993;28:890–895
  51. Rusinek H, De Santi S, Frid D, Tsui W, Tarshish C, Convit A, et al. Regional brain atrophy rate predicts future cognitive decline: 6-year longitudinal MR imaging study of normal aging. Radiology. 2003;229:691–696
  52. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173–177
  53. Silverman DHS, Small GW, Chang CY, Lu CS, Kung de Aburto MA, Chen W, et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA. 2001;286:2120–2127
  54. Small GW, Mazziotta JC, Collins MT, Baxter LR, Phelps ME, Mandelkern MA, et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer's disease. JAMA. 1995;273:942–947
  55. Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD, et al. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J. Neurochem. 1977;28:897–916
  56. Talairach J, Tournoux P. Co-Planar Stereotaxic Atlas of the Human Brain. Stuttgart: Thieme; 1988;
  57. Vander Borght T, Minoshima S, Giordani B, Foster NL, Frey KA, Berent S, et al. Cerebral metabolic differences in Parkinson's and Alzheimer's disease matched for dementia severity. J. Nucl. Med. 1997;38:797–802

PII: S0197-4580(06)00461-1

doi: 10.1016/j.neurobiolaging.2006.12.008

Neurobiology of Aging
Volume 29, Issue 5 , Pages 676-692 , May 2008

Article Tools

* Image Usage & Resolution